Relation of viscous lidocaine combined with propofol deep sedation during elective upper gastrointestinal endoscopy to discharge.

Fusing topical pharyngeal anesthetics (TPAs) to intravenous sedation during esophagogastroduodenoscopy (EGD) has been controversial. This double-blind, randomized, placebo-controlled trial assessed the association of TPA with patient recovery time, post-EGD to discharge. Supplementary aims were to determine the association of TPA with patient and practitioner satisfaction (both measured on a 100-mm visual analog scale), total propofol dose, and side effects. The study included 93 patients (mean age 53.8 years, range 44-67; 37 men and 56 women) undergoing elective EGD at a single academic medical center from September 2015 to October 2016. Urgent or therapeutic EGDs were excluded. Interventions were 7.5 mL 2% lidocaine viscous solution and 7.5 mL placebo solution (3% methylcellulose). There were no statistically significant differences between the lidocaine ( = 46) and placebo ( = 47) groups with respect to recovery time (42 ± 17.8 vs 39 ± 15.9 minutes;  = 0.23), procedure time (6.5 ± 2.7 vs 7 ± 3.6 minutes;  = 0.77), endoscopist satisfaction (83.2 ± 24.4 vs 77 ± 27.7,  = 0.23), patient discomfort (16.6 ± 19.8 vs 24.0 ± 29.7,  = 0.37), or total propofol administered (2.3 ± 1.3 vs 2.3 ± 1.0 mg/kg,  = 0.55). Compared to placebo, topical viscous lidocaine does not appear to delay recovery time or adversely affect sedation-related outcomes.